Loading clinical trials...

Unrelated Donor Stem Cell Transplantation | Clinical Trials | Clareo Health

COMPLETEDNA

Unrelated Donor Stem Cell Transplantation

Allogeneic Hematopoietic Progenitor Cell Transplantation From Unrelated Donors

NCT01364363•Scripps Health

Summary

The purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells from unrelated individuals or cord blood registries.

Detailed Description

same

Eligibility

Age

18 - 69 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\> 18 years of Age
•\< 70 years
•ECOG performance status 0, 1 or 2
•Left Ventricular Ejection Fraction \> 30%
•Creatinine clearance \> 40ml/min
•Transaminases \< 2X normal
•Total bilirubin \< 2X normal
•HIV seronegativity
•Weight \< 70kg for cord blood transplantation
•Ability to cover the cost of the transplant, necessary medications, and transportation/housing.
+1 more criteria

Exclusion Criteria

•Greater than one antigen mismatch at HLA-A, B, C or DR plus one allele mismatch at HLA-A, B, C or DR

Locations (1)

Scripps Green Hospital

La Jolla, California, United States

Key Dates

Start Date

March 1, 2005

Primary Completion Date

July 1, 2015

Completion Date

July 1, 2015

Last Updated

November 23, 2022

Enrollment

ACTUAL participants

Conditions

Severe Aplastic AnemiaParoxysmal Nocturnal HemoglobinuriaAcute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromesMyeloproliferative SyndromesChronic Myelogenous LeukemiaHodgkin's LymphomaNon-Hodgkin's LymphomaMultiple MyelomaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLarge Granulocytic Leukemia

Interventions

Allogeneic transplantation

PROCEDURE

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

NCT05012111

Severe Aplastic AnemiaTelomere Biology Disorders+1 more

View study

RECRUITINGPHASE2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

NCT03520647

Severe Aplastic Anemia (SAA)Hypo-Plastic Myelodysplastic Syndrome (MDS)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 23, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Unrelated Donor Stem Cell Transplantation

Inclusion Criteria

Exclusion Criteria

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

National Longitudinal Cohort of Hematological Diseases

Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission.

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy